Most Popular Stories
- Federal bill would link Medicare hospital pay to quality
- Express Scripts clients being extorted, too
- Moody's says healthcare's vulnerable to economy's ills
- Pay for no extra performance?
- Obama healthcare plan a plus for hospitals, Moody's says
- Wiebking named new president of Provena; Acclaimed scientist preps first skin cancer vax trial;
Poll
Featured Jobs
-
Tennessee Neurologist
StaffPointe, LLC - near Chattanooga , TN -
Phamacy Auditor
Pharm/DUR, Inc. - Philadelphia, PA -
Wisonsin-General Surgeon
Ohrmund Employment Group - Cedarburg, WI -
Wisconsin Physical Therapist
StaffPointe, LLC - Green Bay , WI -
Nevada Family Practice Physician
StaffPointe, LLC - northwest, NV
Events
- World Health Care Congress
April 14-16, 2009 — Washington, DC - World Healthcare Innovation & Technology Congress WHIT v.4.0
Dec 8-10 — Washington, DC
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
Inquiry in backdating scandal broadens
Federal prosecutors announced they are investigating stock options grants at pharmacy benefits manager Caremark Rx, as the corporate backdating scandal gains speed. Shares of UnitedHealth Group fell 3.4 percent yesterday after the company revealed that it is the object of a probe by federal prosecutors. The Wall Street Journal comments: "The entry of the U.S. attorney's office in Manhattan, considered among the most experienced in prosecuting white-collar crimes, signals a significant ratcheting up."
- see this article from the Wall Street Journal (sub. req.)
PLUS: The news of UnitedHealth's latest legal problems appeared to demoralize Wall Street analysts, who had largely been hanging tough. "The company's stock [will] likely weaken [on] this news," says Bank of America analyst Joseph France, "which means that both the intensity and the length of this inquiry could be considerably worse than once expected." Article
ALSO: Meanwhile, the run of legal woes for the industry continues, as the Justice Department announces that it has a problem with the rates Abbott Laboratories and spin-off Hospira (hospital products) charged Medicare and Medicaid for more than a decade. Article
Related Stories
- AMA, SEIU ask court to stop UnitedHealth deal
- SEC backs universal health insurance ballot measure
- Blue plans see 18 percent drop in operating earnings for '07
- CMS to review Medicare Advantage sales commissions
- Health insurers turn to financial services
- $420M settlement for UnitedHealth's McGuire moves ahead
- UnitedHealthcare subsidiaries to pay $800K in fines
- UnitedHealth settles securities suit for $895M
- CA doctors say state health plans made $4.3B in profits
- U.S. carriers expand health insurance businesses into China
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





